Author

J. Coxhead

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 3 Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Approach:genetic perturbation / CRISPR· 2 Organism:mouse· 2

Frequent Co-Authors

A. Filby· 3 shared A. Husain· 2 shared D. McDonald· 2 shared G. Reynolds· 2 shared N. Rajan· 2 shared A. C. M. Khan· 1 shared A. Dubois· 1 shared A. E. Campbell· 1 shared

Activity by Year

2019-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Filby

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Programmed cell death-1 receptor mediated regulation of Tbet+ NK1.1- Innate Lymphoid Cells within the Tumor Microenvironment

M. Lim, C. Lai, G. Mallett, D. McDonald, G. Hulme, S. Laba, A. Shapanis, M. Payne, W. Patterson, M. Alexander, J. Coxhead, A. Filby, R. Plummer, P. Lovat, G. Sciume, , S. Amarnath

This paper identifies Tbet+NK1.1- ILCs in the tumor microenvironment and shows PD-1 regulates their proliferation and anti-tumor function through metabolic changes.

bioRxiv · Sep 21, 2022 · PreprintImmunology

An ex vivo human bone marrow milieu identifies CDH2 as a driver of niche-mediated treatment resistance in leukaemia

D. Pal, H. Blair, S. Boyd, S. Angel, S. Nizami, A. Isa, M. Beckett, R. Nelson, A. Wilson, M. Singh, S. Sankar, R. Tirtakusuma, S. Nakjang, C. Knill, A. Fuller, , J. Vormoor

This study identifies CDH2 as a driver of niche-mediated treatment resistance in leukemia and shows that ADH-1 can effectively target this resistance in preclinical models.

bioRxiv · Jun 18, 2021Cancer Biology

Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway

J. E. Hunter, A. E. Campbell, N. L. Hannaway, S. Kerridge, S. Luli, J. A. Butterworth, H. Sellier, R. Mukherjee, H. D. Thomas, P. J. Brownridge, J. Coxhead, L. Taylor, P. Leary, M. S. R. Hasoon, I. Collins, , N. D. Perkins

The paper identifies a c-Rel and USP1 dependent pathway that regulates CHK1 inhibitor resistance in lymphoma cells.

bioRxiv · May 26, 2021Cancer Biology

Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2

C. F. Hatton, R. A. Botting, M. E. Duenas, I. J. Haq, B. Verdon, B. J. Thompson, J. Stremenova Spegarova, F. Gothe, E. A. Stephenson, A. I. Gardner, S. Murphy, J. Scott, J. P. Garnett, S. Carrie, J. Powell, , C. J. A. Duncan

This study shows that delayed type I and III interferon responses in nasal epithelial cells allow SARS-CoV-2 replication, but pre-infection IFN treatment restricts virus and preserves barrier integrity.

bioRxiv · Feb 17, 2021Immunology

Poised cell circuits in human skin are activated in disease

G. Reynolds, P. Vegh, J. Fletcher, E. Poyner, E. Stephenson, I. Goh, R. Botting, N. Huang, B. Olabi, A. Dubois, D. Dixon, K. Green, D. Maunder, J. Engelbert, M. Efremova, , F. Watt

The paper creates a single-cell atlas of human skin, showing how cell circuits change in inflammatory diseases like atopic dermatitis and psoriasis.

bioRxiv · Nov 5, 2020 · PreprintImmunology

Epigenetic dysregulation underpins tumorigenesis in a cutaneous tumor syndrome.

H. Davies, K. Hodgson, E. Schwalbe, J. Coxhead, N. Sinclair, X. Zou, S. Cockell, A. Husain, S. Nik-Zainal, N. Rajan

The paper identifies epigenetic mutations as drivers of tumorigenesis in CYLD cutaneous syndrome, revealing intra-tumor heterogeneity and metastatic potential.

bioRxiv · Jul 1, 2019 · PreprintCancer Biology